New drug cocktail aims to boost myeloma remission
NCT ID NCT05392946
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called iberdomide combined with three standard treatments (daratumumab, bortezomib, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to find the best dose and see if the combination can kill more cancer cells. About 49 adults will take part, and the study is currently active but not recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug's real-world performance match clinical trial results?
- Can a maintenance drug keep myeloma at bay?
- New hope for frail myeloma patients: phase III trial tests smarter drug combos
- Could a tiny dose of radiation ease myeloma bone pain?
- Could a common allergy pill ease bone pain in myeloma treatment?
- New vaccine aims to train immune system against myeloma